Compare iShares MBS ETF (MBB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Revvity Inc — how do they compare? iShares MBS ETF trades at $93.15, while Revvity Inc trades at $116.39 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares MBS ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| MBB | RVTY | |
|---|---|---|
52-Week High | $96.91 | $117.75 |
52-Week Low | $92.72 | $82.26 |
Market Cap | — | $12.91B |
Sector | — | Technology |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB trades at $93.255 with a modest 0.36% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock has demonstrated consistent dividend payments with recent payouts of $0.34 per share. Institutional interest appears positive with Focus Financial Network increasing its stake by 13.8% during the latest reporting period.
The outlook remains cautious given the bearish technical signals, though steady dividend payments provide income stability. Key risks include market volatility and interest rate sensitivity. Investment opportunity lies in the consistent dividend yield and institutional accumulation, but requires monitoring of technical resistance levels around $93.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
